Skip to main content
Equibles

C. Daniel Myers

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About C. Daniel Myers

C. Daniel Myers was last confirmed as Board Member at KALA BIO, Inc. (KALA) in a filing dated December 30, 2025. Earlier roles on record: Board Member at KALA BIO, Inc. (KALA) until December 19, 2025. KALA BIO, Inc. reported in an 8-K filed February 2, 2026 that C. Daniel Myers resigned as Class III director, effective December 19, 2025. KALA BIO, Inc. reported in an 8-K filed December 29, 2025 that C. Daniel Myers resigned as director. KALA BIO, Inc. reported in an 8-K filed June 23, 2023 that C. Daniel Myers was appointed Class III director, effective June 22, 2023.

“on December 19, 2025, each of (i) Marjan Farid, M.D. and Andrew I. Koven, who were Class I directors of the Company, (ii) Mark Iwicki and Todd Bazemore were Class II directors of the Company, and (iii) C. Daniel Meyers and Howard B. Rosen, who were Class III directors of the Company (collectively, the "Resigning Directors"), tendered their resignations as directors of the Company, effective immediately following the Annual Meeting and upon approval of the Issuance Proposal and the Share Increase Proposal”
KALA BIO, Inc. Form 8-K, filed February 2, 2026 · Read the filing
“each of Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen tendered on December 19, 2025 a conditional resignation from their positions as director effective immediately after the Company's 2025 Annual Meeting if stockholder approval is obtained at such 2025 Annual Meeting”
KALA BIO, Inc. Form 8-K, filed December 29, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.